Description

Overview

KPV is the three-amino-acid sequence Lys-Pro-Val derived from the C-terminal region of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been studied for anti-inflammatory activity without the pigmentation-related signaling associated with full-length alpha-MSH. Experimental work has focused on NF-kB signaling, pro-inflammatory cytokines, intestinal inflammation, epithelial transport, and skin models. Most evidence remains cellular or animal-based.

How It Works

• NF-kB signaling: Experimental studies report reduced activation or nuclear translocation of NF-kB in inflammatory models.
• Cytokine modulation: Research has measured TNF-alpha, IL-6, IL-1beta, and related inflammatory mediators.
• Epithelial effects: Gut and skin models have examined local transport and barrier-associated inflammatory responses.

Research Areas

• Intestinal inflammation models
• Epithelial barrier research
• Skin inflammation
• Innate immune signaling

Research / Study Context

• Cellular inflammation models: Researchers have measured cytokines, transcription-factor activation, and epithelial responses.
• Animal colitis models: Preclinical studies have evaluated inflammation scores, tissue injury, and local peptide delivery.

Key Research Findings

• KPV has reproducible anti-inflammatory signals in experimental models.
• Human clinical evidence is limited.
• Claims should remain focused on research pathways rather than disease treatment.

Related Research

• BPC-157
• LL-37
• Thymosin Alpha-1

Scientific Reference Starter Set

• Peptide Education Hub: KPV profile
• PubMed search: KPV alpha-MSH tripeptide colitis
• PubMed search: KPV NF-kB inflammation